Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 16 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| PAULSON CAPITAL CORP | 4,047,830 | reported | 13 Aug 2015 | tx 1+650,000 |
| Neumora Therapeutics, Inc. | 3,859,898 | reported | 29 Sept 2023 | tx 19+19,160,459−17,424,704 |
| Karuna Therapeutics, Inc. | 1,456,435 | reported | 13 Apr 2021 | tx 21+3,396,891−2,885,416 |
| Verve Therapeutics, Inc. | 1,254,404 | reported | 21 Jun 2021 | tx 6+2,508,809−23,230,337 |
| FATE THERAPEUTICS INC | 1,246,156 | reported | 04 Oct 2013 | tx 7+2,473,188−1,476,925 |
| ADOLOR CORP | 1,207,523 | reported | 17 May 2007 | tx 8+52,736−169,648 |
| Bellerophon Therapeutics, Inc. | 965,660 | reported | 19 Feb 2015 | tx 3+965,660−752,994 |
| Ruthigen, Inc. | 797,506 | reported | 15 Jun 2015 | tx 1+797,506 |
| Vir Biotechnology, Inc. | 584,148 | reported | 30 May 2024 | tx 92+29,043,686−42,972,219 |
| XTERA COMMUNICATIONS, INC. | 166,667 | reported | 13 Sept 2016 | tx 1+166,667 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 01 Aug 2025 | GRANT_AWARD | Prime Medicine, Inc. | 45,000 | — | deriv |
| 01 Aug 2025 | OTHER | Prime Medicine, Inc. | 39,062 | — | deriv |
| 01 Aug 2025 | OTHER | Prime Medicine, Inc. | 45,000 | — | deriv |
| 01 Aug 2025 | GRANT_AWARD | Prime Medicine, Inc. | 39,062 | — | deriv |
| 01 Aug 2025 | PURCHASE | Prime Medicine, Inc. | 3,030,300 | 3.30 USD | first after silence |
| 05 Jun 2025 | GRANT_AWARD | Sana Biotechnology, Inc. | 80,000 | 0.00 USD | deriv |
| 04 Jun 2025 | GRANT_AWARD | Prime Medicine, Inc. | 55,000 | 0.00 USD | deriv |
| 14 Jun 2024 | GRANT_AWARD | Lyell Immunopharma, Inc. | 130,000 | 0.00 USD | deriv |
| 12 Jun 2024 | GRANT_AWARD | Prime Medicine, Inc. | 45,000 | 0.00 USD | deriv |
| 10 Jun 2024 | CONVERSION | Rapport Therapeutics, Inc. | 3,728,738 | 0.00 USD | |
| 10 Jun 2024 | CONVERSION | Rapport Therapeutics, Inc. | 11,924,138 | 0.00 USD | deriv |
| 10 Jun 2024 | CONVERSION | Rapport Therapeutics, Inc. | 20,000,000 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Sana Biotechnology, Inc. | 54,278 | 0.00 USD | deriv |
| 30 May 2024 | GRANT_AWARD | Vir Biotechnology, Inc. | 8,000 | 0.00 USD | |
| 30 May 2024 | GRANT_AWARD | Vir Biotechnology, Inc. | 16,000 | 0.00 USD | deriv |
| 15 Feb 2024 | PURCHASE | Prime Medicine, Inc. | 3,200,000 | 6.25 USD | |
| 08 Feb 2024 | PURCHASE | Sana Biotechnology, Inc. | 727,272 | 5.50 USD | |
| 08 Feb 2024 | PURCHASE | Sana Biotechnology, Inc. | 727,272 | 5.50 USD | |
| 08 Feb 2024 | PURCHASE | Sana Biotechnology, Inc. | 363,637 | 5.50 USD | |
| 28 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 16,841 | 13.06 USD | |
| 29 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 34,560 | 13.98 USD | |
| 28 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 25,110 | 13.69 USD | |
| 26 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 34,000 | 11.73 USD | |
| 27 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 24,504 | 12.31 USD | |
| 25 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 30,773 | 10.80 USD |
7 purchases reported after at least 12 months of silence — most recent on 01 Aug 2025.